<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Protein kinase inhibitors; Tyrosine kinase inhibitors; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Pazopanib; Sorafenib; Sunitinib; Temsirolimus" /><meta name="IX" content="Protein kinase inhibitors; Tyrosine kinase inhibitors; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Pazopanib; Sorafenib; Sunitinib; Temsirolimus" /><title>Protein kinase inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="129966.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="129966.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=129966.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4676.htm">8.1 Cytotoxic drugs</a> &gt; <a href="4758.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="11787.htm" title="Previous: PROCARBAZINE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="129967.htm" title="Next: DASATINIB">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_129966">Protein kinase inhibitors</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i1087.htm" title="Go to appendix 1">Protein Kinase Inhibitors</a>).</div><div><p>Dasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib,
nilotinib, pazopanib, sorafenib, sunitinib, and temsirolimus are protein
kinase inhibitors.</p><div id="_1199889035752"><p><b>Dasatinib</b>, a tyrosine
kinase inhibitor, is licensed for the treatment of chronic myeloid
leukaemia in those who have resistance to or intolerance of previous
therapy, including imatinib. It is also licensed for newly diagnosed
Philadelphia chromosome-positive chronic myeloid leukaemia in the
chronic phase and for acute lymphoblastic leukaemia (Philadelphia
chromosome positive) in those who have resistance to or intolerance
of previous therapy. </p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (April 2007) that the use of dasatinib (<span class="cZ">Sprycel</span>®) in NHS Scotland is restricted to patients in the chronic phase
of chronic myeloid leukaemia.</p></div><div id="_1199889063675"><p><b>Erlotinib</b>, a tyrosine kinase inhibitor, is licensed in combination with gemcitabine
for the treatment of metastatic pancreatic cancer. It is also licensed
for the treatment of locally advanced or metastatic non-small cell
lung cancer after failure of previous chemotherapy and as monotherapy
for maintenance treatment of locally advanced or metastatic non-small
cell lung cancer with stable disease after four cycles of platinum-based
chemotherapy.</p></div><p>The <i><a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790">Scottish Medicines Consortium</a></i> has advised (May 2006) that erlotinib (<span class="cZ">Tarceva</span>®) is accepted for restricted use within NHS Scotland for the treatment
of locally advanced or metastatic non-small cell lung cancer, after
failure of at least one chemotherapy regimen. Erlotinib is restricted
to use in patients who would otherwise be eligible for treatment with
docetaxel monotherapy.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Erlotinib for non-small-cell lung cancer (November
2008)</h3><p>Erlotinib is recommended, as an alternative to docetaxel, as
second-line treatment for locally advanced or metastatic non-small-cell
lung cancer after failure of previous chemotherapy, on the basis that
it is provided by the manufacturer at an overall treatment cost equal
to that of docetaxel. Erlotinib is <b>not</b> recommended
in patients for whom docetaxel is unsuitable or as third-line treatment
after docetaxel.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Erlotinib monotherapy for maintenance treatment of
non-small-cell lung cancer (June 2011)</h3><p>Erlotinib monotherapy is <b>not</b> recommended for
maintenance treatment in people with locally advanced or metastatic
non-small-cell lung cancer who have stable disease after platinum-based
first-line chemotherapy.</p></div><div id="_204151"><p><b>Everolimus</b>, a protein kinase
inhibitor, is licensed for the treatment of advanced renal cell carcinoma
when the disease has progressed despite treatment with vascular endothelial
growth factor-targeted therapy (see NICE guidance below), and for
the treatment of unresectable or metastatic, well- or moderately-differentiated
neuroendocrine tumours of pancreatic origin. It is also licensed for
the treatment of subependymal giant cell astrocytoma associated with
tuberous sclerosis complex in patients who require therapeutic intervention
but are not amenable to surgery.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Everolimus for the second-line treatment of advanced
renal cell carcinoma (April 2011)</h3><p>Everolimus is <b>not</b> recommended for the second-line
treatment of advanced renal cell carcinoma.</p></div></div><div id="_204193"><p><b>Gefitinib</b>, a tyrosine
kinase inhibitor, is licensed for the treatment of locally advanced
or metastatic non-small cell lung cancer with activating mutations
of epidermal growth factor receptor.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Gefitinib for the first-line treatment of locally
advanced or metastatic non-small-cell lung cancer (July 2010)</h3><p>Gefitinib is recommended as an option for the first-line treatment
of locally advanced or metastatic non-small-cell lung cancer if the
patient tests positive for the epidermal growth receptor tyrosine
kinase (EGFR-TK) mutation and the manufacturer provides gefitinib
at the fixed price agreed under the patient access scheme.</p></div></div><div id="_1199889133692"><p><b>Imatinib</b>, a tyrosine kinase inhibitor, is licensed for the treatment of newly
diagnosed chronic myeloid leukaemia where bone marrow transplantation
is not considered first-line treatment, and for chronic myeloid leukaemia
in chronic phase after failure of interferon alfa, or in accelerated
phase, or in blast crisis (see NICE guidance below). It is also licensed
for the treatment of c-kit (CD117)-positive unresectable or metastatic
malignant gastro-intestinal stromal tumours (GIST), and as adjuvant
treatment following resection of c-kit (CD117)-positive GIST, in patients
at significant risk of relapse. Imatinib is licensed for the treatment
of newly diagnosed acute lymphoblastic leukaemia in combination with
other chemotherapy, and as monotherapy for relapsed or refractory
acute lymphoblastic leukaemia. Imatinib is also licensed for the treatment
of unresectable dermatofibrosarcoma protuberans and for patients with
recurrent or metastatic dermatofibrosarcoma protuberans who cannot
have surgery.</p><p>Imatinib is also licensed for the treatment of myelodysplastic/myeloproliferative
diseases associated with platelet-derived growth factor receptor gene
rearrangement and for the treatment of advanced hypereosinophilic
syndrome and chronic eosinophilic leukaemia.</p></div><p>The <i><a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790">Scottish Medicines Consortium</a></i> has advised (March 2002) that imatinib (<span class="cZ">Glivec</span>®) should be used for chronic myeloid leukaemia only under specialist
supervision in accordance with British Society of Haematology guidelines
(November 2001).</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Imatinib for chronic myeloid leukaemia (October 2003)</h3><p>Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive
chronic myeloid leukaemia in the chronic phase and as an option for
patients presenting in the accelerated phase or with blast crisis,
provided that imatinib has not been used previously.</p><p>Where imatinib has failed to stop disease progression from chronic
phase to accelerated phase or to blast crisis, continued use is recommended
only as part of further clinical study.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Imatinib for the adjuvant treatment of gastro-intestinal
stromal tumours (August 2010)</h3><p>Imatinib is not recommended for the adjuvant treatment of gastro-intestinal
stromal tumours after surgery.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Imatinib for the treatment  of unresectable and/or
metastatic gastro-intestinal stromal tumours (October 2004)</h3><p>Imatinib 400 mg daily is recommended as first-line management
of KIT (CD117)-positive unresectable or metastatic, or both, gastro-intestinal
stromal tumours. Continued therapy is recommended only if a response
to initial treatment [as defined by Southwest Oncology Group criteria
available at <a href="http://www.nice.org.uk/TA86" title="external link">www.nice.org.uk/TA86</a>] is achieved within 12 weeks. Patients who have responded should
be assessed at 12-week intervals. Discontinue if tumour ceases to
respond.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Imatinib for the treatment of unresectable and/or
metastatic gastro-intestinal stromal tumours (November 2010)</h3><p>Imatinib 600 mg daily or 800 mg daily is not recommended for
unresectable or metastatic, or both, gastro-intestinal stromal tumours
whose disease has progressed after treatment with imatinib 400 mg
daily.</p></div><div id="_201426"><p><b>Lapatinib</b>, a tyrosine kinase
inhibitor, is licensed for the treatment of advanced or metastatic
breast cancer in patients with tumours that overexpress human epidermal
growth factor receptor-2 (HER2). It is indicated, in combination with
capecitabine, for patients who have had previous treatment with an
anthracycline, a taxane, and trastuzumab, or for postmenopausal women
in combination with an aromatase inhibitor <a title="BNF:sub-sub-section: Breast cancer" href="4821.htm#_4821">section 8.3.4.1</a>.</p></div><div id="_200920"><p><b>Nilotinib</b>, a tyrosine
kinase inhibitor, is licensed for the treatment of newly diagnosed
chronic myeloid leukaemia in the chronic phase, and also for patients
with chronic or accelerated phase chronic myeloid leukaemia who have
resistance to or intolerance of previous therapy, including imatinib.</p></div><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (February 2008) that nilotinib (<span class="cZ">Tasigna</span>®) is accepted for restricted use within NHS Scotland for the treatment
of chronic-phase chronic myeloid leukaemia in adults resistant to
or intolerant of at least one previous therapy, including imatinib,
and (July 2011) for the treatment of adults with newly diagnosed chronic
myeloid leukaemia in the chronic phase.</p><div id="_213739"><p><b>Pazopanib</b>, a tyrosine kinase
inhibitor, is licensed for advanced renal cell carcinoma, as first-line
treatment and for patients who have had previous treatment with cytokine
therapy for advanced disease.</p></div><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (February 2011) that pazopanib (<span class="cZ">Votrient</span>®) is accepted for restricted use within NHS Scotland for the first-line
treatment of advanced renal cell carcinoma.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Pazopanib for the first-line treatment of advanced
renal cell carcinoma (February 2011)</h3><p>Pazopanib is recommended as a first-line treatment option for
people with advanced renal cell carcinoma who have <b>not</b> received prior cytokine therapy.</p></div><div id="_1199889158709"><p><b>Sorafenib</b>, an inhibitor
of multiple kinases, is licensed for the treatment of advanced renal
cell carcinoma when treatment with interferon alfa or interleukin-2
has failed or is contra-indicated (but see NICE Guidance below). It
is also licensed for the treatment of hepatocellular carcinoma.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Sorafenib for the treatment of advanced hepatocellular
carcinoma (May 2010)</h3><p>Sorafenib is <b>not</b> recommended for the treatment
of advanced hepatocellular carcinoma in patients for whom surgical
or locoregional therapies have failed or are unsuitable.</p></div><div id="_1199889183162"><p><b>Sunitinib</b>, a tyrosine
kinase inhibitor, is licensed for the treatment of advanced or metastatic
renal cell carcinoma (but see NICE Guidance, below). It is also licensed
for the treatment of unresectable or metastatic malignant gastro-intestinal
stromal tumours, after failure of imatinib, and for the treatment
of unresectable or metastatic pancreatic neuroendocrine tumors.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (October 2009 and April 2011) that sunitinib (<span class="cZ">Sutent</span>®) is accepted for restricted use within NHS Scotland
for the treatment of unresectable or metastatic malignant gastro-intestinal
stromal tumours after failure of imatinib and for unresectable or
metastatic pancreatic neuroendocrine tumours.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Sunitinib for advanced or metastatic renal cell carcinoma
(March 2009)</h3><p>Sunitinib is recommended as first-line treatment for advanced
or metastatic renal cell carcinoma in patients who are suitable for
immunotherapy and have an Eastern Cooperative Oncology Group performance
status of 0 or 1.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Sunitinib for the treatment of gastro-intestinal
stromal tumours (September 2009)</h3><p>Sunitinib is recommended as an option for treatment in patients
with unresectable or metastatic gastro-intestinal tumours if imatinib
treatment has failed because of resistance or intolerance, and the
cost of sunitinib for the first treatment cycle is met by the manufacturer.</p></div><div id="_204194"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Bevacizumab (first-line), sorafenib (first- and second-line),
sunitinib (second-line) and temsirolimus (first-line) for the treatment
of advanced or metastatic renal cell carcinoma (August 2009)</h3><p>Bevacizumab, sorafenib, and temsirolimus are not recommended
as first-line treatments for people with advanced or metastatic renal
cell carcinoma.</p><p>Sorafenib and sunitinib are not recommended as second-line treatments
for people with advanced or metastatic renal cell carcinoma.</p></div></div><div id="_201704"><p><b>Temsirolimus</b> is a protein kinase inhibitor licensed for the first-line treatment
of advanced renal cell carcinoma (see NICE Guidance above), and for
the treatment of relapsed or refractory mantle cell lymphoma. Hypersensitivity
reactions, including some life-threatening and rare fatal reactions,
are associated with temsirolimus therapy, usually during administration
of the first dose. Symptoms include flushing, chest pain, dyspnoea,
apnoea, hypotension, loss of consciousness, and anaphylaxis. Where
possible, patients should receive an intravenous dose of antihistamine
30 minutes before starting the temsirolimus infusion. The infusion
may have to be stopped temporarily for the treatment of infusion-related
effects—consult product literature for appropriate management. If
adverse reactions are not managed with dose delays, a dose reduction
should be considered—consult product literature.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_129967"><a href="129967.htm" title="DASATINIB">DASATINIB</a></li><li id="_129403"><a href="129403.htm" title="ERLOTINIB">ERLOTINIB</a></li><li id="_203889"><a href="203889.htm" title="EVEROLIMUS">EVEROLIMUS</a></li><li id="_203890"><a href="203890.htm" title="GEFITINIB">GEFITINIB</a></li><li id="_106029"><a href="106029.htm" title="IMATINIB">IMATINIB</a></li><li id="_201425"><a href="201425.htm" title="LAPATINIB">LAPATINIB</a></li><li id="_200921"><a href="200921.htm" title="NILOTINIB">NILOTINIB</a></li><li id="_208714"><a href="208714.htm" title="PAZOPANIB">PAZOPANIB</a></li><li id="_129969"><a href="129969.htm" title="SORAFENIB">SORAFENIB</a></li><li id="_129971"><a href="129971.htm" title="SUNITINIB">SUNITINIB</a></li><li id="_201443"><a href="201443.htm" title="TEMSIROLIMUS">TEMSIROLIMUS</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="11787.htm">Previous: PROCARBAZINE</a> | <a class="top" href="129966.htm#">Top</a> | <a accesskey="]" href="129967.htm">Next: DASATINIB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>